THOMAS MCCORMACK: Open Payments
NPI 1740298728 · BOGART, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$21,356 in 184 payments from 20 companies in 2025. Trend: 2023 $27,435 · 2024 $33,054 · 2025 $21,356
Honoraria: $14,600Food & beverage: $3,415Travel & lodging: $3,282Education: $59
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 16 | $11,347 |
| Supernus Pharmaceuticals, Inc. | 23 | $7,381 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 27 | $409 |
| Neurocrine BioSciences, Inc. | 20 | $375 |
| Otsuka America Pharmaceutical, Inc. | 11 | $212 |
| Vanda Pharmaceuticals Inc. | 10 | $204 |
| ABBVIE INC. | 17 | $201 |
| Alkermes, Inc. | 7 | $160 |
| Lundbeck LLC | 8 | $157 |
| Janssen Pharmaceuticals, Inc | 7 | $156 |
Products named: Auvelity, Qelbree, CAPLYTA, INGREZZA, REXULTI, FANAPT, VRAYLAR, ABILIFY ASIMTUFII.
Industry payments across GA — which companies pay providers there.
